Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
A 33-year-old user has been on finasteride for 10 years with great results and recently increased their oral minoxidil dose to 5 mg to improve hair thickness and possibly regrow hair. They are considering microneedling and a hair transplant to enhance their hairline and temples, despite already having significant improvement.
A 25-year-old shared progress after a year using oral finasteride, topical minoxidil, and microneedling, noting significant hair improvement despite periodic shedding. The user experienced body hair loss as a side effect but reported no other issues and plans to continue the treatment.
The user started using 5 mg oral minoxidil and 1 mg finasteride daily, along with microneedling and applying lavender oil, saw palmetto, and pumpkin seed oil to the scalp. They report significant hair regrowth within a few months.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
The user stopped using Alfatradiol after 4 months due to no hair improvement and side effects like dry scalp and gallbladder pain. They are considering trying topilutamide, which is suggested as an alternative.
Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.
A user shared their positive experience with a 5% minoxidil and 0.1% finasteride topical serum for hair loss, noting improvements in hair density and new growth within 2.5 months. They also mentioned using red light therapy, vitamin D+K2 supplements, and an all-natural shampoo.
The user is treating alopecia areata with 1.25mg oral minoxidil daily and topical mometasone furoate, considering increasing the dose or adding finasteride, though finasteride is not typically used for this condition. A gluten-free diet is suggested, and alternatives like Olumiant are mentioned.
The user shared 60-day progress using 5% topical minoxidil, 1mg finasteride, and recently started microneedling with a derma stamp. Users commented on the difficulty of seeing changes due to hair length and even thinning.
Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.
The user is experiencing hair regrowth and increased hair thickness after using supplements like biotin, zinc, selenium, and a complex with various natural ingredients, along with topical caffeine. They are considering using topical minoxidil and mesotherapy in the future.
A 35-year-old male experienced significant hair improvement using microneedling, finasteride, minoxidil, and keto shampoo. He adjusted his microneedling routine for better results.
User shares 6.5 months of progress using topical finasteride 0.1% and minoxidil 10%, along with lasercomb, dermaroller, Nizoral, scalp massager, and biotin. They seek feedback on their results.
The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.
Hair loss treatments, specifically the use of Alfatradiol as an over-the-counter topical 5AR inhibitor that has been shown to be effective in stopping hair loss without side effects. Other treatments discussed include Minoxidil, finasteride and RU58841.
Significant hair improvement was achieved using 1.25mg finasteride and 5mg oral minoxidil daily, with no side effects. The user increased the minoxidil dosage to 7.5mg after noticing minor thinning and plans to continue the routine.
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.
The conversation discusses Shiseido's RepliCel Hair-01 technology for hair regeneration, which aims to stop hair loss with minimal regrowth. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses hair regrowth using daily 1g finasteride and topical minoxidil for 5 months, with occasional dermarolling. Users note visible progress and suggest continuing the routine.
The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.
A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.
The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.